Keyphrases
Reporting System
100%
Chimeric Antigen Receptor T-cell Therapy
100%
Dermatological Adverse Effects
100%
Pharmacovigilance Analysis
100%
Axicabtagene Ciloleucel
100%
Tisagenlecleucel
100%
FDA Adverse Event Reporting System (FAERS)
50%
Reporting Odds Ratio
50%
Cutaneous Eruption
50%
Adverse Event Reporting System Database
50%
Reporting Rate
16%
High Mortality
16%
Adverse Events
16%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
16%
Clinical Practice
16%
Drug Adverse Events
16%
Am(III)
16%
Median Time
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
Severe Adverse Events
16%
Relapsed or Refractory
16%
Adverse Events Profile
16%
Cell Infusion
16%
Timely Identification
16%
Off-label Indications
16%
Cytokine Release Syndrome
16%
Disproportionality Analysis
16%
Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
16%
Dermatologic Toxicity
16%
Diffuse Large B-cell Lymphoma Cells
16%
Duplicate Report
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Chimeric Antigen Receptor
100%
Dermatological Agent
100%
Pharmacovigilance
100%
Axicabtagene Ciloleucel
85%
FDA Adverse Event Reporting System
42%
Acute Lymphoblastic Leukemia
14%
Adverse Drug Reaction
14%
Diffuse Large B Cell Lymphoma
14%
Cytokine Release Syndrome
14%
Disproportionality Analysis
14%
Toxicity and Intoxication
14%
Medicine and Dentistry
Adverse Event
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Dermatological Agent
100%
Pharmacovigilance
100%
Axicabtagene Ciloleucel
60%
Odds Ratio
30%
Infusion
10%
Diffuse Large B-Cell Lymphoma
10%
Acute B-Cell Lymphoblastic Leukemia
10%
Adverse Drug Reaction
10%
Effector Cell
10%
Chimeric Antigen Receptor T-Cell
10%
Cytokine Release Syndrome
10%
Toxicity and Intoxication
10%